Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW to Invite Candidate Products for “Sakigake” Designation System
March 31, 2015
- MHLW Reiterates Caution on Skin Disorders for Lamictal: Safety Bulletin
March 31, 2015
- Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
- PMDA Launches Consultation Services for Academia-Led Trials
March 30, 2015
- MHLW OKs 32 Products Including Sovaldi, Lenvima
March 27, 2015
- Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
- Govt OKs AMED’s 5-Year Plan Articulating Support for 200 Drug Seed Development Projects
March 26, 2015
- Cabinet OKs NIBIO Director Yoneda as Chief of Merged Institute
March 25, 2015
- Ministry Requires Addition of Thrombocytopenia as Serious ADR to Januvia
March 25, 2015
- Lawmakers to Form Nonpartisan Group to Spur Biosimilar Use
March 24, 2015
- Kitasato Daiichi Sankyo Vaccine to Remain in State Vaccine Project
March 24, 2015
- PMDA Pledges Cooperation to Promote Commercialization of Seeds: Chief Executive
March 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 9 - 22
March 23, 2015
- MHLW OKs Pfizer’s Jzoloft for PTSD Indication, Other Drugs
March 23, 2015
- 196 “Designated Intractable Diseases” Likely to Be Eligible for Subsidies from July
March 20, 2015
- Physicians Becoming Picky about Generic Brands: Survey
March 19, 2015
- Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
- Japan to Build Dementia Patients Registration System: WHO Ministerial Conference
March 19, 2015
- Chuikyo Approves Reimbursement for RAS Gene Test Kit; Listing Scheduled for April
March 19, 2015
- Chuikyo Approves Listing of ViiV Healthcare’s HIV Treatment Triumeq; Listing Scheduled for March 25
March 19, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…